Dabrafenib plus trametinib in patients with BRAF V600–mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial

BACKGROUND: Dabrafenib plus trametinib (D+T) improves outcomes in BRAF V600–mutant metastatic melanoma without brain metastases; however, activity of D+T has not been studied in active melanoma brain metastases (MBM). Here, we report results from the phase 2 trial COMBI-MB. Our aim was to build upon...

詳細記述

保存先:
書誌詳細
出版年:Lancet Oncol
主要な著者: Davies, Michael A, Saiag, Philippe, Robert, Caroline, Grob, Jean-Jacques, Flaherty, Keith T, Arance, Ana, Chiarion-Sileni, Vanna, Thomas, Luc, Lesimple, Thierry, Mortier, Prof Laurent, Moschos, Stergios J, Hogg, David, Márquez-Rodas, Iván, Del Vecchio, Michele, Lebbé, Céleste, Meyer, Nicolas, Zhang, Ying, Huang, Yingjie, Mookerjee, Bijoyesh, Long, Georgina V
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5991615/
https://ncbi.nlm.nih.gov/pubmed/28592387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30429-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料